

# TABLE OF CONTENTS

February 23, 2009

No. 2128

## BUSINESS

- 1 Novartis Gears Up to Enter the Top Three in Japan
  - Drug Lag Shortened to 2.48 Years
  - Conducting More Multinational Clinical Trials
  - Aiming at No. 3 Place in Oncology
- 3 Five Factors Responsible for Drug Lag: Mr Sekiguchi
  - Pharma Industry Is a Driver of Japanese Economy
- 4 Astellas to Reinforce Its Global Development System
- 4 MTPC Continues Cost-cutting Efforts
- 5 Meiji Seika to Develop Antibody Drugs for Infectious Diseases in Earnest
  - Increasing MRs by 100 to Launch 2 New Products
  - NHI Price Cuts for Meiact, Depromel Hit Business
- 6 Olmetec Goes to Front on Both GP and HP Markets: Rep Track Survey
- 6 **BUSINESS NEWS IN BRIEF**
  - MTPC to Comarket Adair with GSK
  - Eisai Licenses LIVACT from Ajinomoto in Asia
  - GSK to Import Relenza for an Additional 2 Million Persons
  - Clio Science Ties Up with CRO in Shanghai
  - UPSHE Ties Up with Yakugaku Seminar to Transform Inexperienced People into MRs
  - FALCO to Acquire Shimeno Yakkyoku in Hokuriku Region
- 8 **3-Qtr Business Results: 3**
  - Nippon Shinyaku: Robust Growth in Sales of 10.6%
  - Zeria: Sales Down 3.8%
  - ASKA: Sharp Drop in Profits despite Slight Gain in Sales
  - JT: Licensing Deals Make Up for Slump of Torii
  - Rohto: Domestic Sales of Skin Care Products Drive Business
  - Taiyo: Sales Up 13.4% with Strengthened Sales Force
  - Sawai: Sales Up 16.4% to ¥33.4 Bil.
  - Towa: Sales Up 13.7% Driven by Good Sales of New Products
- 10 **Commentary**
  - Aggressive Overseas Investments Affect Business of Top-4 Pharmas

## REGULATORY

- 12 FDA Approves Gout Treatment from Teijin/Takeda
- 12 PMDA Announces Draft of 2nd Mid-Term Plan
  - To Double Safety Measure Contribution Rate from April
  - To Provide 1,200 Consultation Services per Year by FY2011
  - To More Closely Ally with Authorities from Other Countries
  - Exception to Working Rule for Ex-Employees of Companies to Be Extended One Year
- 12 **REGULATORY NEWS IN BRIEF**
  - Chugai to Apply for Cancer-Related Anemia for Epogin
  - UCB to Submit Additional Data to FDA for Cimzia BLA
  - PFSB Designates 2 Orphan Drugs

## R&D

- 14 Enhancing Japan's Presence in Multinational Clinical Trials
  - Use of Control Drugs at Doses Not Approved in Japan Permissible: PMDA Official
  - PFSBJapan Must Participate from Stage of Protocol Drafting
- 15 Bayer Schering to Transfer iPS Cell-Related Rights to iZumi Bio
- 16 Motesanib to Be Developed for Non-Squamous Cell Carcinoma Only
- 16 **R&D NEWS IN BRIEF**
  - Oncolys Presents PIa Results for Festinavir
  - Takeda, XOMA Expand Antibody Technology Collaboration
  - Otsuka's Basic Research Center in Shanghai
  - Erbitux Effective for KRAS Wild-Type Tumors: Merck Serono

## SELF-MEDICATION

- 17 Pharmacists Are Consumers' Final Line of Defense
  - JPA Concerned about Large Gaps in Success Rate in Exam for Registered Drug Salespersons
- 18 SSP: Hythiol-C Struggles due to Tougher Competition
  - Applications Pending for 2 Direct/Switch OTC Drugs
- 18 **SELF-MEDICATION NEWS IN BRIEF**
  - JODA Mulls over Safety Measures Necessary to Have Online Sale of All OTC Drugs Permitted
  - Best Efforts Must Be Made to Provide Written Info. on Designated Class 2 OTC Drugs
  - JACDS to Prepare Its Own GL for Proper Sale of OTC Drugs
  - Rakuten's Chairman Mikitani to Personally Attend Discussion Group Meeting
  - Top Leaders of Rakuten, JPA to Attend Debates on Online Sale
- 20 **OPINION**
  - The 12 Steps to Marketing Success: Philip Carrigan

## MEDICAL DEVICES

- 21 3-Track System to Be Introduced to Eliminate "Device Lag"
- 21 "Deposit Sales" System Discussed by Council Members
- 22 **MEDICAL DEVICE NEWS IN BRIEF**
  - Teijin Embarks on Homecare Business in Spain
  - Suzuken Allies with Medifacts to Provide QT Interval Measurement Service
  - SMU, IBL Jointly Develop Kit for Diagnosis of GVHD
  - Asahi Kasei Medical to Construct New Plant for Planova

## GENERIC

- 23 **GENERIC NEWS IN BRIEF**
  - Teva-Kowa Announces Members of Management Team
  - Taiyo Recalls Generic Fosfomycin Product
  - JSHP to Clarify Its Stance on Use of Generics